Negash Daniel T, Dhingra Vinay K, Copland Michael, Griesdale Donald, Henderson William
Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Vasc Endovascular Surg. 2011 Aug;45(6):504-10. doi: 10.1177/1538574411407935. Epub 2011 Jun 5.
Acute kidney injury is a common finding among patients in the intensive care unit (ICU) and is an independent predictor of mortality. The optimal intensity and timing of continuous renal replacement therapy (CRRT), in critically ill patients remain unclear. The purpose of this study was to conduct a systematic review and meta-analysis of all prospective randomized controlled trials (RCTs) to determine the effect of intensity of CRRT on the survival of patients with acute renal failure (ARF) in ICU setting.
Search strategy and data source. Electronic databases were searched on MEDLINE (through February 2010), ISIWeb of Science, and Cochrane Central Register of Controlled Trials (2010); Pub Med ''Related articles.'' Trial authors were also contacted for additional information. Study selection and data abstraction. All prospective clinical trials comparing the intensity of CRRT in adult patients with ARF and with explicit reporting of mortality were included. Three authors independently evaluated articles for eligibility and extracted data on study quality and outcomes. Meta-analysis used a random-effects model.
Of the 322 citations, 5 trials (n = 2402) were included in the meta-analysis, which met all the inclusion and exclusion criteria. Meta-analysis showed that in critically ill patients with acute kidney injury, the high-dose CRRT did not reduce mortality at 28 days. (risk ratio [RR], 0.88; 95% confidence interval [CI], 0.70-1.11; P = 0.28).
In critically ill patients with acute kidney injury, the high-dose CRRT did not reduce mortality at 28 days.
急性肾损伤在重症监护病房(ICU)患者中很常见,并且是死亡率的独立预测因素。对于危重症患者,持续肾脏替代治疗(CRRT)的最佳强度和时机仍不明确。本研究的目的是对所有前瞻性随机对照试验(RCT)进行系统评价和荟萃分析,以确定CRRT强度对ICU环境下急性肾衰竭(ARF)患者生存的影响。
检索策略与数据来源。检索了MEDLINE(截至2010年2月)、ISI科学网和Cochrane对照试验中心注册库(2010年)等电子数据库;还检索了PubMed的“相关文章”。同时联系试验作者以获取更多信息。研究选择与数据提取。纳入所有比较ARF成年患者CRRT强度并明确报告死亡率的前瞻性临床试验。三位作者独立评估文章的入选资格,并提取关于研究质量和结果的数据。荟萃分析采用随机效应模型。
在322篇文献中,有5项试验(n = 2402)纳入荟萃分析,这些试验均符合所有纳入和排除标准。荟萃分析表明,在急性肾损伤的危重症患者中,高剂量CRRT在28天时并未降低死亡率。(风险比[RR],0.88;95%置信区间[CI],0.70 - 1.11;P = 0.28)。
在急性肾损伤的危重症患者中,高剂量CRRT在28天时并未降低死亡率。